Table 1.
Main characteristics of the study population.
| N | Median Age (IQR) |
Sex M/F |
Diabetes N (%) |
Hypertension N (%) |
Obesity N (%) |
Cardiovascular Disease N (%) |
Asthma N (%) |
|
|---|---|---|---|---|---|---|---|---|
| Astrazeneca | 95 | 50 (44–57) | 43/52 | 10 (10.5) | 15 (15.8) | 6 (6.3) | 3 (3.2) | 6 (6.3) |
| Sputnik V | 86 | 55 (50–59) | 35/51 | 22 (26.5) | 24 (27.9) | 4 (4.7) | 5 (5.8) | 4 (4.7) |
| Moderna | 63 | 43 (41–48) | 26/37 | 6 (9.5) | 4 (6.3) | 4 (6.3) | 0 (0.0) | 1 (1.6) |
| Pfizer-BioNTech | 119 | 56 (51–63) | 55/64 | 31 (26.1) | 28 (23.5) | 15 (12.6) | 9 (7.6) | 4 (3.4) |
| Sinovac | 55 | 55 (49–60) | 26/29 | 10 (18.2) | 10 (18.2) | 5 (9.1) | 2 (3.6) | 4 (7.3) |
| Sinopharm | 83 | 49 (48–51) | 39/44 | 14 (16.9) | 12 (14.5) | 9 (10.8) | 4 (4.8) | 6 (7.2) |
| All vaccines | 501 | 51 (47–58) | 224/277 | 93 (18.6) | 93 (18.6) | 43 (8.6) | 23 (4.6) | 25 (5) |